Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells

Fig. 1

Deregulation of ZSCAN18 expression in GC is correlated with poor prognosis and high methylation. A Bioinformatics analysis of TCGA database (http://ualcan.path.uab.edu) between tumor tissues (red) and normal tissues (blue) in various cancers. BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; PCPG: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; THCA: thyroid carcinoma; THYM: thymoma; STAD: stomach adenocarcinoma; UCEC: uterine corpus endometrial carcinoma. B Bioinformatics analysis from the public datasets (GSE33335) in adjacent non-tumor tissues and tumor tissues. C mRNA expression levels of ZSCAN18 in GC tissue and matched adjacent non-tumor tissue samples (n = 30) are determined by qRT-PCR. D ZSCAN18 expression score analysis of IHC staining in GC tissues and adjacent non-tumor tissues (n = 83). Score of (−) or (+) is classified as negative, while score of (++) or (+++) is classified as positive (see above). E Kaplan–Meier curves show the association of overall survival rate of GC patients with ZSCAN18 expression. Green: GC patients with negative expression (n = 49, median survival, 21 months); orange: GC patients with positive expression (n = 34, median survival, 37 months, p < 0.001, log-rank test). F Multivariate analysis shows independent prognosis factors. G Bioinformatics analysis from the public datasets (GSE30601) in adjacent non-tumor tissues and tumor tissues. H Methylation status and levels of ZSCAN18 in GC tissue (n = 97) and adjacent non-tumor tissue (n = 6) samples are determined by MassARRAY. I The methylation levels of ZSCAN18 were detected by MassARRAY in GC tissues and adjacent non-tumor tissue samples, the CpG11.19.39, CpG23.37.44, CpG26.27 and CpG45.46 are significantly different. J Kaplan–Meier curves show the association of overall survival rate of GC patients with ZSCAN18 hypermethylation. K Multivariate analysis shows independent prognosis factors. Each experiment was performed in triplicate and repeated at least three times. Data were represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page